PHF5A consideration as a promising therapeutic biomarker for the management of cancer malignancies is imperatively attributed to its pivotal role in cancer initiation and progression along with its effective participation in spliceosome and non-spliceosome related attributes responsible for the regulation of CSCs. This evidence concerns the gene PHF5A and cancer.